More study of heart imaging agent risks urged
SILVER SPRING, Maryland (Reuters) - Makers of contrast agents used to enhance echocardiogram images need to conduct larger studies to better evaluate the heart risks seen in some patients, a U.S. panel of medical experts said on Tuesday.
<p><img src="http://feeds.feedburner.com/~a/reuters/healthNews?i=o1Z9OR" border="0"></img> (http://feeds.feedburner.com/~a/reuters/healthNews?a=o1Z9OR)</p><div class="feedflare">
<img src="http://feeds.feedburner.com/~f/reuters/healthNews?i=vi6J3I" border="0"></img> (http://feeds.feedburner.com/~f/reuters/healthNews?a=vi6J3I) <img src="http://feeds.feedburner.com/~f/reuters/healthNews?i=vpMZ9i" border="0"></img> (http://feeds.feedburner.com/~f/reuters/healthNews?a=vpMZ9i) <img src="http://feeds.feedburner.com/~f/reuters/healthNews?i=2aQQBi" border="0"></img> (http://feeds.feedburner.com/~f/reuters/healthNews?a=2aQQBi)
</div><img src="http://feeds.feedburner.com/~r/reuters/healthNews/~4/319221435" height="1" width="1"/>
http://feeds.feedburner.com/~r/reuters/healthNews/~3/319221435/idUSN2438050020080624